CA3049967C - ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS - Google Patents

ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS

Info

Publication number
CA3049967C
CA3049967C CA3049967A CA3049967A CA3049967C CA 3049967 C CA3049967 C CA 3049967C CA 3049967 A CA3049967 A CA 3049967A CA 3049967 A CA3049967 A CA 3049967A CA 3049967 C CA3049967 C CA 3049967C
Authority
CA
Canada
Prior art keywords
seq
antibodies
subject
ige
hlaaiges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3049967A
Other languages
English (en)
French (fr)
Other versions
CA3049967A1 (en
Inventor
Andrew Saxon
Ke Zhang
Original Assignee
Sixal Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62789396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3049967(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sixal Inc, University of California San Diego UCSD filed Critical Sixal Inc
Publication of CA3049967A1 publication Critical patent/CA3049967A1/en
Application granted granted Critical
Publication of CA3049967C publication Critical patent/CA3049967C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3049967A 2017-01-06 2018-01-05 ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS Active CA3049967C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Publications (2)

Publication Number Publication Date
CA3049967A1 CA3049967A1 (en) 2018-07-12
CA3049967C true CA3049967C (en) 2024-10-01

Family

ID=62789396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049967A Active CA3049967C (en) 2017-01-06 2018-01-05 ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS

Country Status (6)

Country Link
US (2) US11518818B2 (https=)
EP (1) EP3565587A4 (https=)
JP (2) JP7128191B2 (https=)
AU (1) AU2018205484B2 (https=)
CA (1) CA3049967C (https=)
WO (1) WO2018129248A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
HK1048127A1 (en) 2000-01-14 2003-03-21 Daiichi Pharmaceutical Co., Ltd. Novel peptide and screening method by using the same
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
EP1718669A4 (en) * 2004-02-02 2007-10-10 Tanox Inc IDENTIFICATION OF NEW IGE EPITOPES
CN101203241B (zh) * 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
WO2015195631A1 (en) 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3089260A1 (en) * 2018-01-22 2019-07-25 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Also Published As

Publication number Publication date
EP3565587A1 (en) 2019-11-13
JP2022172170A (ja) 2022-11-15
US11518818B2 (en) 2022-12-06
EP3565587A4 (en) 2020-12-16
CA3049967A1 (en) 2018-07-12
US20190322766A1 (en) 2019-10-24
JP7128191B2 (ja) 2022-08-30
WO2018129248A1 (en) 2018-07-12
US20230090487A1 (en) 2023-03-23
JP7461420B2 (ja) 2024-04-03
AU2018205484A1 (en) 2019-08-01
AU2018205484B2 (en) 2024-11-21
JP2020505334A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
US9849165B2 (en) Oligomer-specific amyloid beta epitope and antibodies
AU2021201759A1 (en) Anti-complement C1s antibodies and uses thereof
US10155820B2 (en) Anti-endoglin antibodies and uses thereof
US9926375B2 (en) Anti-endoglin antibodies and uses thereof
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN106164675B (zh) 检测人类骨膜蛋白的新型测定
ES2994127T3 (en) Anti-pd-1 antibodies
CN104039832B (zh) 抗磷酰胆碱的新抗体
BR112021006123A2 (pt) anticorpos anti-sinucleína
JP2025093954A (ja) ヒト化抗－ｃ５ａ抗体
CN103906532B (zh) 结合磷酰胆碱（pc）和/或pc结合物的抗体
US20230090487A1 (en) Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
US20160168268A1 (en) Anti-Immunoglobulin E Antibodies and Methods of Using Thereof
JP2022172170A5 (https=)
CN119546631A (zh) 用于治疗支气管扩张的抗PcrV和Psl双特异性抗体
US20230220053A1 (en) ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
RU2820628C2 (ru) Белки, связывающие глюкагоновые рецепторы, и способы их применения
Khatri Structural and Immunological Characterization of Inhaled Allergens and Their Complexes With Antibodies
Nandakumar Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220802

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20240926

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20241001

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229